In parallel, clinical trials could assess the combination of PARP inhibitors with NLRP3-targeted therapies in patients with high NLRP3 expression, evaluating treatment efficacy by monitoring tumor progression, DNA repair markers (e.g., γ-H2AX), and patient response rates. Here, NLRP3 is linked to neoplasm.